ORTHOPEDIATRICS CORP KIDS revenue by segment, product and geography
In its fiscal year ending 2025-12-31, ORTHOPEDIATRICS CORP reported revenue across 3 products and services; the largest, Traumaand Deformity, was $166M, 70.4% of the filed sum (+14.6% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Traumaand Deformity$166M70.4%+14.6% yoy
- Spine$66M27.9%+19.8% yoy
- Sports Medicine And Other$4M1.7%-10.1% yoy
Members sum to the consolidated $236M for this period.
- United States$186M78.9%+15.7% yoy
- Outside the United States$49.9M21.1%+14.6% yoy
Members sum to the consolidated $236M for this period.
- Trauma And Deformity$43M72.5%+13.7% yoy
- Spine$15.4M26.0%+13.0% yoy
- Sports Medicine And Other$875K1.5%-0.6% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.